Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Minimal-access surgery uses a smaller opening in the body to remove the tumor than is used in standard surgery. It is not yet known whether minimal-access surgery to remove the bladder is more effective than standard surgery to remove the bladder in treating patients with bladder cancer.

PURPOSE: This randomized phase II trial is studying standard surgery to see how well it works compared with minimal-access surgery in treating patients with bladder cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer

NCT02699853

Stage 0is Bladder Urothelial Carcinoma Stage I Bladder Urothelial Carcinoma Stage II Bladder Urothelial Carcinoma +1 more

TERMINATED NA

Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer

NCT02252393

Recurrent Bladder Cancer Stage 0 Bladder Cancer Stage I Bladder Cancer +2 more

WITHDRAWN NA

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

NCT01157676

Bladder Cancer Requiring Cystectomy

COMPLETED NA

Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy

NCT03049410

Bladder Cancer

UNKNOWN NA

Protocol of the Italian Radical Cystectomy Registry

NCT04228198

Bladder Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To determine the feasibility of randomizing patients with bladder cancer to undergo an open cystectomy versus a minimal-access cystectomy (laparoscopic or robotic cystectomy).

Secondary

* To assess the safety and efficacy of laparoscopic or robotic cystectomy and the reasons for non-acceptance of randomization.
* To collect safety and toxicity data, including measures of postoperative morbidity and surgical complications. (Exploratory)
* To investigate anatomical lymph node dissection (an indicator for oncological clearance) and completeness of cancer surgery. (Exploratory)
* To determine the quality of life of these patients using EORTC QLQ-C30 and EORTC QLQ-BLM30 questionnaires. (Exploratory)

OUTLINE: This is a multicenter study. Patients who consent to the interview-only (but not randomization) undergo a qualitative interview exploring factors relating to this decision. Patients who consent to randomization are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo an open radical cystectomy.
* Arm II: Patients undergo a minimal-access radical cystectomy (laparoscopic or robotic).

Patients complete quality-of-life questionnaires (EORTC QLQ-C30 and EORTC QLQ-BLM30) at baseline and at 4 weeks, 6 weeks, 8 weeks, 3 months, and 6 months after completion of study therapy. Blood, urine, and tissue samples are collected from some patients at baseline and during study for laboratory analysis.

After completion of study treatment, patients are followed up at 6 weeks, 3 months, and 6 months.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

PROJECTED ACCRUAL: A total of 92 patients (72 patients for the randomized portion and 20 for the interview-only portion) are accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

questionnaire administration

Intervention Type OTHER

quality-of-life assessment

Intervention Type PROCEDURE

robot-assisted laparoscopic surgery

Intervention Type PROCEDURE

therapeutic conventional surgery

Intervention Type PROCEDURE

therapeutic laparoscopic surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histopathologically confirmed bladder cancer, including any of the following cell types:

* Urothelial cell (transitional cell) carcinoma
* Squamous cell carcinoma
* Adenocarcinoma
* Stage pT1, pT2, or pT3 disease OR mobile bladder mass on bimanual examination under anesthesia
* No enlarged nodes or distant metastases on CT or MRI scan of the abdomen and pelvis
* No upper urinary tract disease

PATIENT CHARACTERISTICS:

* American Society of Anesthesiologist (ASA) status 1-3
* Life expectancy \> 24 months
* Not pregnant or nursing
* Negative pregnancy test
* No concurrent disease that would render the patient unsuitable for the trial
* No presence of urosepsis

PRIOR CONCURRENT THERAPY:

* May have received prior neoadjuvant chemotherapy provided study surgery is performed between 3 and 10 weeks from the date of the completion of chemotherapy treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No